EDS
Evan David Seigerman BMO Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $640 |
12%
upside
| Outperform |
4 Aug ‘25
1 month ago |
|
2
Replimune Group
REPL
$494M
| $6.33 | $2 |
68%
downside
| Underperform |
23 Jul ‘25
1 month ago |
|
3
Neurogene
NGNE
$285M
| $19.95 | $26 |
30%
upside
| Outperform |
12 Jun ‘25
2 months ago |
|
4
Merus
MRUS
$5.1B
| $67.47 | $110 |
63%
upside
| Outperform |
23 May ‘25
3 months ago |
|
5
Acadia Pharmaceuticals
ACAD
$4.26B
| $25.26 | $28 |
11%
upside
| Outperform |
19 May ‘25
3 months ago |
|
6
Arvinas
ARVN
$575M
| $7.83 | $10 |
28%
upside
| Outperform |
5 May ‘25
4 months ago |
|
7
Novo Nordisk
NVO
$245B
| $55.23 | $64 |
16%
upside
| Market Perform |
17 Apr ‘25
4 months ago |
|
8
Merck
MRK
$212B
| $84.71 | $96 |
13%
upside
| Market Perform |
5 Feb ‘25
7 months ago |
|
9
AbbVie
ABBV
$375B
| $212.56 | $215 |
1%
upside
| Outperform |
3 Feb ‘25
7 months ago |
|
10
Amgen
AMGN
$153B
| $283.64 | $346 |
22%
upside
| Outperform |
29 Jan ‘25
7 months ago |
|
11
Structure Therapeutics
GPCR
$1.27B
| $22.08 | $100 |
353%
upside
| Outperform |
7 Jun ‘24
1 year ago |
|
12
Pfizer
PFE
$141B
| $24.88 | $36 |
45%
upside
| Outperform |
2 May ‘24
1 year ago |
|
13
Candel Therapeutics
CADL
$274M
| $5 | $3 |
40%
downside
| Outperform |
15 May ‘23
2 years ago |
|
14
Eli Lilly
LLY
$652B
| $727.21 | $396 |
46%
downside
| Outperform |
6 Sep ‘22
3 years ago |
|